Synoptics Health, a new division of Synoptics, a world leader in the development and manufacture of innovative digital imaging systems for scientific applications, has announced the launch of its innovative ProReveal Test, a rapid in-situ fluorescence-based method of detecting proteins on surgical instruments.
New ProReveal Ultra-Sensitive Test for Detecting Protein on Surgical Instruments Introduced at MEDICA
At MEDICA, Synoptics Health experts were showing the patented, ultra-sensitive ProReveal Test, which combines an integrated ProReveal Protein Test Kit and a ProReveal Viewer with easy-to-use touch screen and software. In just two simple spray and see steps, users can detect nanogram levels of protein contamination, no matter where it is located on their entire surgical instrument, in less than 5 minutes.
The ProReveal Test has been developed over four years in partnership with scientists at Queen Mary University of London and is now available in the UK from Peskett Solutions and across the rest of the world from Synoptics Health. The ProReveal Test aligns with the protein contamination testing recommendations in the UK’s new NHS CFPP-01-01 consultation document.
Paul Ellwood, CEO of Synoptics Health explained: “We are delighted to be introducing our revolutionary new test at the leading show for medical technology innovation. The ProReveal Test uses very sensitive, yet cost-effective fluorescence technology and will tell you exactly where, and how much protein is on your surgical instrument. This is a significant quality enhancement from current testing available and there isn’t any other affordable fluorescence-based test designed for this application that is commercially available, so it really is a first at MEDICA.”
Ellwood continued: “We look forward to welcoming visitors to stand F12 at MEDICA and to discussing with them how they could integrate the ProReveal Test into their workflow to help them optimize their decontamination process and thus ensure they continue to supply clean, safe surgical instruments, which comply with current and future quality standards.”
Company websiteSynoptics Health